Vironix Health has Partnered with The Landon Pediatric Foundation to Bring AI-Healthcare Technology to Southern California
Digital Health Company Vironix Health has teamed up with LPF to increase access to affordable healthcare and promote adoption of remote patient care technology throughout Southern California. Vironix’s proprietary remote monitoring products help patients with heart & lung conditions (Heart Failure, Asthma, COPD, Covid-19, & Acute Respiratory Illness) to identify and intervene early on acute health deterioration events. The merging of Vironix’s real-time health tracking and interpretation software with expert managed care staff has been shown to deliver significant patient health improvement with high patient participation and little to no added burden on physicians and hospital/clinic facilities.
In the words of Dr. Sumanth Swaminathan, Vironix’s Co-Founder and CEO, “the moment for real-time, personalized, precision medicine is now. We, as a global community, have an opportunity to save countless lives and reduce hundreds of billions of dollars in preventable healthcare costs by arming patients with the awareness and decision support needed to intervene on disease degeneration before it’s too late. Vironix is truly excited to be partnering with the Landon Foundation and the best chronic care medical professionals in the country to deliver affordable, at-home, life-saving preventative care technologies to Southern California’s chronic illness population.”
This new partnership merges expertise in disease progression and patient care among Pulmonary & Cardiovascular physician specialists in Ventura CA with cutting-edge remote monitoring and machine learning technologies at Vironix Health. LPF will provide healthcare professionals, pilot execution, and patient enrollment services across Ventura CA, Malibu CA, and the greater Los Angeles area. Vironix will provide biometric measurement devices, managed care services, AI-enabled monitoring software, and data storage/interpretation capabilities. The partnership will initially target ~ 10,000 patients.
Dr. Christopher Landon, Director of the Landon Foundation and forty year practicing pulmonologist, said, “Being able to monitor, predict, and intervene early on these horrible flare-ups of respiratory illness is invaluable to patient care, not only for patients’ sakes but for their sons, daughters, partners, colleagues, and everyone who depends on them. Vironix’s remote monitoring program has the right blend of clinical rigor, ease-of-use, and affordability to meaningfully lower healthcare costs and raise quality-of-life in Southern California.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more